Cancer Research Center Groningen (CRCG)

University of Groningen > Faculty of Medical Sciences > Cancer Research Center Groningen (CRCG)

Contact information

Ant. Deusinglaan 1
Building 3217 ('de Brug'), Room 7.21
9713 AV
  • Phone: +31 50 363 4734

Organisational unit profile

Fundamental, Clinical and Translational Cancer Research.
The Cancer Research Center Groningen (CRCG) was established in 2012. The aim is to translate fundamental insights in oncogenesis and tumour behaviour from basic research into cancer prevention, improvement of early detection of cancer, and better treatment for cancer patients.

The mission of the CRCG is to clarify the molecular mechanisms that determine malignant transformation in a broad spectrum of tumors and to translate these fundamental insights into improved early detection and treatment of cancers. This will ultimately lead to personalized cancer therapy, thus reducing the unintended side effects of treatment on normal tissues and improving the quality of life of cancer survivors.

The CRCG was founded in 2012 as an independent research institute of the University Medical Center Groningen. Four key research programmes have been established:

  1. Damage and Repair in Cancer Development and Cancer Treatment (DARE);
  2. Guided Treatment in optimal Selected cancer patientsTranslational and Clinical research in Oncology (GUTS);
  3. Stem cells, Aging, Leukemia and Lymphoma (SALL);
  4. TARgeted Gynaecologic Oncology  (TARGON).

These programmes are supported by 60 PIs and 139 PhD or MD/PhD students who participate in the UMCG’s Graduate School of Medical Sciences (GSMS). The various programs are characterized by a strong interaction between basic and translational research programs, as shown by joint research meetings and projects.

  1. Real world experience and biomarkers of nivolumab in dutch advanced renal-cell carcinoma patients.

    Verhaart, S. L., L.-Van Herpen, C. M., Oosting, S., Van der Veldt, A., Osanto, S. & Aarts, M. J. B. 20-May-2018 In : Journal of Clinical Oncology. 36, 15, 1 p.

    Research output: Contribution to journalMeeting Abstract

  2. Comparative biodistribution analysis across four different Zr-monoclonal antibody tracers-The first step towards an imaging warehouse

    Bensch, F., Smeenk, M. M., van Es, S. C., de Jong, J. R., Schröder, C. P., Oosting, S. F., Lub-de Hooge, M. N., Menke-van der Houven van Oordt, C. W., Brouwers, A. H., Boellaard, R. & de Vries, E. G. E. 2018 In : Theranostics. 8, 16, p. 4295-4304 10 p.

    Research output: Contribution to journalArticle

  3. Multi-scenario robustness evaluation; transition to a 'proton proof' alternative to PTV evaluation

    Korevaar, E. W., Scandurra, D., Gelderman, M., Kierkels, R. G., Knopf, A. C., Both, S., Unipan, M., Eenink, M. G. C. & Langendijk, J. A. Apr-2018 In : Radiotherapy and Oncology. 127, p. S1073-S1074 2 p.

    Research output: Contribution to journalMeeting Abstract

View all (8,825) »

  1. Dataset: Inter-laboratory agreement of the Cervista HPV HR test with a second cut-off at default setting of 1.93 (A) and at new setting of 5.0 (B)

    Boers, A. (Creator), Slagter-Menkema, L. (Creator), Hemel, van, B. (Creator), Belinson, J. L. (Creator), Ruitenbeek, T. (Creator), Buikema, H. J. (Creator), Klip, H. (Creator), Ghyssaert, H. (Creator), Zee, van der, A. (Creator), Bock, de, T. (Creator), Schuurs-Wisman, B. (Creator), Schuuring, E. (Creator), University of Groningen, 22-Jul-2014


  2. Thyroid Cancer

    Links, T. (Creator), University of Groningen, 2018


View all (6) »

  1. Mandema-stipendium

    Rudolf Fehrmann (Recipient), 2012

    Prize: Fellowship awarded competitively

  2. MD/PhD scholarship

    Rudolf Fehrmann (Recipient), 2006

    Prize: Fellowship awarded competitively

View all (15) »

  1. Alphavirus-based vaccines from benchto bedside

    Daemen, T. (Speaker)

    Activity: Talk or presentationInvited talk

  2. IAEA (External organisation)

    Elsinga, P. (Member)

    Activity: ProfessionalMembership of committee

  3. NVGCT Nederlandse Vereniging voor Gen- en Celtherapie (External organisation)

    Daemen, T. (Member)

    Activity: ScientificMembership of committee

View all (153) »

Press / Media
  1. College

    Anke Berg, van den


    1 media contribution

    Press/Media: Public Engagement Activities

  2. Nieuwe ontwikkelingen in hematologie, MDS, AML, translationeel.

    Jan Jacob Schuringa


    1 media contribution

    Press/Media: Public Engagement Activities

  3. Experimentele hematologie verfijnt kijk op leukemie

    Jan Jacob Schuringa


    1 item of media coverage

    Press/Media: Public Engagement Activities

View all (31) »

View graph of relations

ID: 12296270